Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.79 |
| ▸ | HTT | P42858 | 11/20 | 0.79 |
| ▸ | RAB9A | P51151 | 9/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 8/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.79 |
| ▸ | NPC1 | O15118 | 6/20 | 0.79 |
| ▸ | MEN1 | O00255 | 6/20 | 0.79 |
| ▸ | ATM | Q13315 | 5/20 | 0.79 |
| ▸ | MITF | O75030 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | GAA | P10253 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | XBP1 | P17861 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.69 |
| ▸ | CDC25A | P30304 | 3/20 | 0.69 |
| ▸ | CDC25B | P30305 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506683 | 0.89 | MAPT (1.00) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL29633261 | 0.89 | MAPT (1.00) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL8663288 | 0.86 | MAPT (0.74) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL4868219 | 0.86 | MAPT (1.00) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL7240445 | 0.86 | MAPT (0.74) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL4873496 | 0.86 | MAPT (1.00) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL12283294 | 0.83 | MAPT (0.71) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL16297206 | 0.82 | KMT2A (0.65) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL12283357 | 0.82 | MAPT (0.73) | MAPTHTTRAB9AMAPK1NPSR1 | |
| SCHEMBL6501763 | 0.82 | MAPT (1.00) | MAPTHTTRAB9AMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021092-A1 | STRUCTURE-BASED DESIGN OF A NOVEL CLASS OF DRUGS FOR NEURODEGENERATIVE DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021092-A1 | STRUCTURE-BASED DESIGN OF A NOVEL CLASS OF DRUGS FOR NEURODEGENERATIVE DISEASE | SNCA, MAPT, PSEN2 | MAPT 2/4885HTT 42/4885RAB9A 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.